US EditionPublished • loading... • Updated
Update on givinostat NHS England decision – and what it means for families
Summary by Action Duchenne
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Update on givinostat NHS England decision – and what it means for families
The decision on whether Duchenne muscular dystrophy treatment, givinostat, can be offered on the NHS in England for patients aged 6 years and older has been on pause since late 2025, and that pause is now continuing. We know this delay is frustrating, but there are encouraging signs: final discussions are progressing, and the review is now waiting for new rules in April that could help more treatments be approved. Givinostat has been looked at b…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
